28.02.2018 • News

Syngenta and Nippon Soda Agree Seeds Deal

Syngenta, part of the ChemChina group since June 2017, has entered into a...
Syngenta, part of the ChemChina group since June 2017, has entered into a global licensing agreement with Nippon Soda for Picarbutrazox, a fungicide with a novel mode of action that has been developed by the Japanese company

Swiss seeds specialist Syngenta, part of the ChemChina group since June 2017, has entered into a global licensing agreement with Nippon Soda for Picarbutrazox, a fungicide with a novel mode of action that has been developed by the Japanese company.

Chinami Yokota, director of Nippon Soda’s development department, said the deal with Syngenta will broaden the use of Picarbutrazox beyond foliar application.

According to the companies, Picarbutrazox shows “robust and reliable performance” for controlling Pythium and seedling blight diseases under many different cropping systems.  Pythium, also known as root rot, damping off or water mold, is a fungus-like organism that affects hydroponic crops.

Tackling Pythium, they said, allows farmers to adopt reduced or no-tillage cropping systems protecting the soil, avoid the costs of replanting and benefit from better germination, strong stand establishment and higher yields.

“Picarbutrazox will strengthen Syngenta’s leading Pythium-control portfolio Mefenoxam and Azoxystrobin technology in corn, soybeans, canola, oilseed rape, cereals and other crops,” said Ioana Tudor, global head of Syngenta Seedcare.

The first commercial launch of Picarbutrazox for seed treatment is expected in the US and Canada in 2019.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.